Genus PLC ADR GENSY
Trading Information
- Previous Close Price
- $31.25
- Day Range
- $28.38–28.38
- 52-Week Range
- $28.38–44.14
- Bid/Ask
- $19.55 / $61.29
- Shares Outstanding
- 65.37M
- Market Cap
- $1.88B
- Volume/Avg
- 3,271 / 3,158
Key Statistics
- Price/Earnings (Normalized)
- 19.79
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- 1.54%
- Dividend Yield (Forward)
- 1.54%
- Dividend Payment Schedule
- Apr, Dec
- Total Yield
- 1.54%
Company Profile
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,300
- Website
- https://www.genusplc.com
Valuation
|
Metric
|
GENSY
|
|---|---|
Price/Earnings (Normalized) | 19.79 |
Price/Book Value | 1.85 |
Price/Sales | 2.16 |
Price/Cash Flow | 16.66 |
Price/Earnings
GENSY
Financial Strength
|
Metric
|
GENSY
|
|---|---|
Quick Ratio | 1.42 |
Current Ratio | 2.22 |
Interest Coverage | 20.65 |
Quick Ratio
GENSY
Profitability
|
Metric
|
GENSY
|
|---|---|
Return on Assets (Normalized) | 7.70% |
Return on Equity (Normalized) | 12.52% |
Return on Invested Capital (Normalized) | 10.95% |
Return on Assets
GENSY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|QX&#@< | LOCK|fP&Jr | $129B | |||
| Moderna Inc
MRNA
| LOCK|x!^Nz<! | LOCK|^s | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|l#Q#%! | LOCK|Sc^@ | $77B | |||
| argenx SE ADR
ARGX
| LOCK|X<<jTQ> | LOCK|&<k | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FFxcT>> | LOCK|!XD | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qD@CpC | LOCK|S@J#? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X?m<X?<P | LOCK|lL!ZK | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$%YxMFL | LOCK|q^g | $24B | |||
| Incyte Corp
INCY
| LOCK|M#t$#> | LOCK|Db | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>BqQ^!% | LOCK|n@? | $14B |
United States